Evidence map›Paper›PMID 26028619›Full record

ArticleThe European respiratory journal2015

Taking the "I" out of IPF.

Susan K Mathai, David A Schwartz

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The European respiratory journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Susan K MathaiDivision of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver, Aurora, CO, USA susan.mathai@ucdenver.edu.
David A SchwartzDivision of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver, Aurora, CO, USA Dept of Medicine, University of Colorado Denver, Aurora, CO, USA.

Funding

MULTIDISCIPLINARY RESPIRATORY DISEASES RESEARCH TRAININGT32HL007085 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ELLEN L BURNHAM, LISA A MAIER · 1985 to 2026
$21.6M
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)R01HL097163 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI FINGERLIN, TASHA E., SCHWARTZ, DAVID ALBERT · 2009 to 2018
$16.4M
MUC5B, a novel therapeutic target for Idiopathic Pulmonary Fibrosis (IPF)UH2HL123442 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2014 to 2015
$3.0M
Functional Genetics in Idiopathic Pulmonary FibrosisR33HL120770 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2016 to 2018
$1.6M
Functional Genetics in Idiopathic Pulmonary FibrosisR21HL120770 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2014 to 2015
$424k
Genetic and Epigenetic Changes in MUC5B and Fibrosing Interstitial Lung DiseaseI01BX001534 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI SCHWARTZ, DAVID ALBERT · 2013 to 2016
–
BLRD VA I01 BX001534NHLBI NIH HHS R01 HL097163NHLBI NIH HHS R01-HL097163NHLBI NIH HHS R210HL120770NHLBI NIH HHS R21 HL120770NHLBI NIH HHS T32 HL007085NHLBI NIH HHS UH2 HL123442NHLBI NIH HHS UH2-HL123442
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HumansIdiopathic Pulmonary Fibrosis

Identifiers

PMID26028619
PMCPMC4556422

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.